If the FDA complies with its advisory panel’s recommendations, Johnson & Johnson, Bayer and other drugmakers would be required to pull their oral medications containing phenylephrine from store shelves, a move that would force consumers to switch to the behind-the-counter pseudoephedrine products or to phenylephrine-based nasal sprays and drops.
With only the drops and nasal sprays available, the FDA would have to work with drugstores, pharmacists and other health providers to educate consumers about the remaining options for treating congestion, warns the panel of government advis
Rear the entire story:
